---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015255"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:51:29.240558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end

## Summary
- Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.
- Cash & equivalents $2.07B as of June 30, 2022 (down from $2.38B at Dec 31, 2021); cash used for R&D and pre-commercial costs.
- exa-cel: CLIMB-111/121 fully enrolled; regulatory submissions for SCD & TDT planned in Europe/UK by end of 2022; FDA discussions ongoing.
- Enrollment continuing for CTX110 (CD19+), CTX130 (CD70) in solid/hematologic tumors; CTX110 data expected in 2022.
- Next-gen CAR-T INDs (CTX131, CTX112) expected by year-end; VCTX211 CTA for T1D in H2 2022.

## SEC filing metadata
- accession: 0000950170-22-015255
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/0000950170-22-015255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/crsp-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015255
- JSON: https://secwatch.observer/filing/0000950170-22-015255.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015255.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.